Veru (NASDAQ:VERU) Stock Picked Up by Analysts at Westpark Capital

Analysts at Westpark Capital started coverage on shares of Veru (NASDAQ:VERU) in a research report issued on Tuesday, Marketbeat Ratings reports. The firm set a “buy” rating on the stock.

A number of other research analysts also recently issued reports on the stock. Weiss Ratings upgraded shares of Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday. Wall Street Zen lowered shares of Veru from a “hold” rating to a “sell” rating in a research note on Sunday, September 27th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Veru has a consensus rating of “Moderate Buy” and an average target price of $24.50.

Veru Stock Performance

Shares of NASDAQ VERU traded up $0.02 during midday trading on Tuesday, reaching $2.49. The stock had a trading volume of 133,607 shares, compared to its average volume of 733,414. The firm has a market cap of $42.37 million, a price-to-earnings ratio of -3.60 and a beta of -1.21. Veru has a twelve month low of $2.05 and a twelve month high of $7.33. The company’s 50 day moving average price is $2.54 and its 200 day moving average price is $2.53.

Veru (NASDAQ:VERU) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.02. Equities analysts forecast that Veru will post -1.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. FNY Investment Advisers LLC bought a new position in shares of Veru in the second quarter worth approximately $328,000. Renaissance Technologies LLC bought a new position in Veru in the 1st quarter worth about $153,000. Finally, Royal Bank of Canada boosted its stake in Veru by 69.3% in the 1st quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after purchasing an additional 5,008 shares in the last quarter. 47.16% of the stock is owned by hedge funds and other institutional investors.

About Veru

Veru Inc is a clinical-stage biopharmaceutical company focused on developing medicines for obesity, oncology and related conditions. The company’s research programs are designed to address cancer-related muscle loss and treatment challenges, as well as the loss of lean muscle that can accompany significant weight reduction.

Veru’s lead investigational product, enobosarm, is an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function.